Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
- 7 August 2020
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 148 (2) , 307-319
Abstract
Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two‐sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low‐density lipoprotein [LDL] and high‐density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels (P < 5 × 10−8) were identified as instrumental variables, and assessed using genome‐wide association study data from the Endometrial Cancer Association Consortium (12 906 cases and 108 979 controls) and the Global Lipids Genetic Consortium (n = 188 578). Mendelian randomization analyses found genetically raised LDL cholesterol levels to be associated with lower risks of endometrial cancer of all histologies combined, and of endometrioid and non‐endometrioid subtypes. Conversely, higher genetically predicted HDL cholesterol levels were associated with increased risk of non‐endometrioid endometrial cancer. After accounting for the potential confounding role of obesity (as measured by genetic variants associated with body mass index), the association between genetically predicted increased LDL cholesterol levels and lower endometrial cancer risk remained significant, especially for non‐endometrioid endometrial cancer. There was no evidence to support a role for triglycerides in endometrial cancer development. Our study supports a role for LDL and HDL cholesterol in the development of non‐endometrioid endometrial cancer. Further studies are required to understand the mechanisms underlying these findings.Keywords
Funding Information
- Fred Hutchinson Cancer Center
- Susan G. Komen
- Haukeland Universitetssjukehus
- Mayo Foundation for Medical Education and Research
- Cancer Council Tasmania (ID#457636, ID#403031)
- National Cancer Institute (U19 CA148065‐01)
- National Heart, Lung, and Blood Institute
- Ovarian Cancer Research Fund
- Breast Cancer Research Foundation
- Canadian Institutes of Health Research (MOP‐86727)
- Department of Defence, Australian Government (W81XWH‐10‐1‐0341)
- Foundation for the National Institutes of Health (CA128978)
- Cancer Research UK (C490/A10124, C8197/A16565, C5047/A10692, C5047/A15007, C5047/A8384, C1281/A12014, C12292/A11174, C1287/A10710, C1287/A10118)
- National Health and Medical Research Council (ID#339435, G0000934, ID#1031333, ID#552402, ID#1109286)
This publication has 44 references indexed in Scilit:
- Hypertriglyceridemia is Frequent in Endometrial Cancer SurvivorsJapanese Journal of Clinical Oncology, 2013
- Endometrial Cancer Risk Factors by 2 Main Histologic SubtypesAmerican Journal of Epidemiology, 2012
- HDL of Patients with Type 2 Diabetes Mellitus Elevates the Capability of Promoting Breast Cancer MetastasisClinical Cancer Research, 2012
- Case–Control Study of the Metabolic Syndrome and Metabolic Risk Factors for Endometrial CancerCancer Epidemiology, Biomarkers & Prevention, 2011
- The association between metabolic abnormality and endometrial cancer: A large case-control study in ChinaGynecologic Oncology, 2010
- Metabolic Syndrome and Endometrial CarcinomaAmerican Journal of Epidemiology, 2010
- Serum lipids and endometrial cancer risk: Results from the HUNT‐II studyInternational Journal of Cancer, 2009
- c-Jun N-Terminal Kinase 2 Deficiency Protects Against Hypercholesterolemia-Induced Endothelial Dysfunction and Oxidative StressCirculation, 2008
- Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC)Endocrine-Related Cancer, 2007
- NF-κB functions as a tumour promoter in inflammation-associated cancerNature, 2004